Ionis Pharmaceuticals, Inc. has announced that its partnership with AstraZeneca has led to the approval of WAINZUA (eplontersen) by the European Union (EU)

WAINZUA (eplontersen) EU-Approved for Stage 1/2 Hereditary Transthyretin-Mediated Amyloido

Ionis Pharmaceuticals, Inc. has announced that its partnership with AstraZeneca has led to the approval of WAINZUA (eplontersen) by the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy.…

Read MoreWAINZUA (eplontersen) EU-Approved for Stage 1/2 Hereditary Transthyretin-Mediated Amyloido
BASF, Somaiya Vidyavihar, and Indian Chemical Council Showcase

BASF, Somaiya Vidyavihar, and Indian Chemical Council Showcase Progress of We-Chemie Program 2024

BASF, Somaiya Vidyavihar, and Indian Chemical Council Celebrate Progress of We-Chemie Program BASF India, in collaboration with Somaiya Vidyavihar (SVV) and the Indian Chemical Council (ICC), proudly marks a significant milestone in the We-Chemie program, celebrating its accomplishments since its…

Read MoreBASF, Somaiya Vidyavihar, and Indian Chemical Council Showcase Progress of We-Chemie Program 2024
AskBio Advances Gene Therapy Trial for Limb-Girdle Muscular Dystrophy with Dosing of Second Cohort

AskBio Advances Gene Therapy Trial for Limb-Girdle Muscular Dystrophy with Dosing of Second Cohort

AskBio Advances Gene Therapy Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 AskBio Inc., a leading gene therapy company wholly owned by Bayer AG, has announced a significant milestone in its Phase 1/Phase 2 LION-CS101 clinical trial for the investigational gene…

Read MoreAskBio Advances Gene Therapy Trial for Limb-Girdle Muscular Dystrophy with Dosing of Second Cohort